BRCA1 and breast neoplasm: Consistent with the subtyping in our clinical trial samples, few BRCA1 germline mutation related breast tumors in TCGA database are immunomodulatory (7% versus 21% of TNBC from non-carriers) and most BRCA2 germline mutation related breast cancers do not classify as TNBC (12 out of 15, 80%) (Fig. 4b and c).